Product Description
Bemarituzumab is currently being evaluated in combination with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing advanced-stage GEA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32167861/)
Mechanisms of Action: FGFR2 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Breakthrough Therapy - Gastrointestinal Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 21
Highest Development Phases
Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer
Phase 2: Cervical Cancer|Cholangiocarcinoma|Endometrial Cancer|Head and Neck Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer
Phase 1: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-512484-31-00 | P2 |
Unknown Status |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2028-03-31 |
|
| BEMARA | P2 |
Not yet recruiting |
Adenocarcinoma|Esophageal Cancer |
2027-09-01 |
|
| jRCT2031210669 | P3 |
Recruiting |
Esophageal Cancer|Adenocarcinoma|Gastrointestinal Cancer |
2027-01-26 |
|
| 20210098 | P3 |
Unknown Status |
Gastrointestinal Cancer|Esophageal Cancer |
2027-01-04 |